Benzene derivatives

Details Benzene derivatives Benzene derivatives

1997-07-23

1998-09-15

Geist, Gary

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acids and salts thereof

560 18, 560 45, C07C22900, C07C32100

Patent

active

058081445

DESCRIPTION:

BRIEF SUMMARY
DESCRIPTION

1. Technical Field
The present invention relates to new benzene derivatives, pharmacologically acceptable salts thereof or pharmacologically acceptable solvates of the above-mentioned benzene derivatives and salts thereof, pharmaceutical compositions comprising same as active ingredients, and pharmaceutical applications of the compositions. More particularly, the present invention relates to new benzene derivatives in which three benzene moieties are bonded through specific bonding groups, pharmacologically acceptable salts thereof or pharmacologically acceptable solvates of the above-mentioned benzene derivatives and salts thereof, pharmaceutical compositions comprising same as an active ingredient, and pharmaceutical applications of the compositions. The new benzene derivatives, salts thereof and solvates of the benzene derivatives and salts thereof exhibit excellent inhibitory activity against production of IgE antibodies and are useful as prophylactic or therapeutic medicines for allergic diseases.
2. Background Art
In various allergic diseases represented by asthma and atopic dermatitis, it is known that various chemical mediators represented by leucotriene and thromboxane perform a large role in the allergic reactions. The allergic reactions are derived from binding (sensitization) of a Fc region of the immunoglobulin E (IgE) antibodies with receptors of cell membranes. When an allergen penetrates into the body in the sensitized conditions, the chemical mediators are released by bonding the allergen with the IgE antibodies on the cell membranes, and thus the allergic diseases occur. In fact, it is known that the concentration of the IgE antibodies in the serum or tissue of the patients with the allergic diseases is higher than that of normal persons. Further, it is known that in the patients with the allergic diseases, a messenger RNA of interleukin 4 (IL-4) is produced in lymphocytes, and the messenger RNA performs an important role on the production of the IgE antibodies. The sthenia in the production of the IgE antibodies through the IL-4 is considered to greatly influence deterioration of pathosis of the diseases. Accordingly, if the production of the IgE antibodies could be inhibited, it is possible that the prophylaxis and/or therapy of the allergic diseases can be greatly promoted. However, as a therapeutic medicine for the allergic diseases, histamine antagonists, which belong to the chemical mediators and release-inhibiters (sodium chromoglycate) of the chemical mediators from the cells, are mainly used, and medicines for preventing or treating the allergic diseases by inhibiting the production of the IgE antibodies have not yet been subjected to practical use. Namely, if a new inhibitor for the production of the IgE antibodies could be obtained, it could block a step before the release of the chemical mediators, and the allergic diseases could be prevented and/or treated in an etiotropic way.
Japanese Unexamined Patent Publication No. 1-287,066 discloses that certain compounds having both a naphthalene moiety and an anthranilic acid moiety, for example, N-(2-naphthoyl)anthranilic acid have an anti-allergic activity or 5-lipoxygenase-inhibiting activity. The compounds described in the above-mentioned publication are, however,-characterized by having the naphthalene structure. Also, the above-mentioned publication does not disclose or suggest whether or not the compounds have the IgE antibody production-inhibiting activity.
Also, Japanese Unexamined Patent Publication No. 63-270634 discloses that certain compounds having both a naphthalene moiety and an anthranilic acid moiety have a 5-lipoxygenase-inhibiting activity and anti SRS-A activity. The compounds described in the above-mentioned publication are, however, characterized in that, in the compounds, the naphthalene moiety and the anthranilic acid moiety are bonded with each other through an alkyl chain. Also, the above-mentioned publication includes no statement concerning the IgE antibody production-inhibiting performance o

REFERENCES:
Database CAPLUS, No. 120:134055, Oe et al., `Preparation of arylalkananilides as ACAT inhibitors (WO9315043),`abstract, Aug. 5, 1993.

Affiliated with

Also associated with

Rating

Benzene derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzene derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzene derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-89938